ArticleOncoimmunology
Novel insights into the mechanism of action of lenalidomide.
Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma.Frontiers in oncology · 2026Article
- Review
- Trial Watch-Small molecules targeting the immunological tumor microenvironment for cancer therapy.Oncoimmunology · 2016Review
- Trial Watch-Immunostimulation with cytokines in cancer therapy.Oncoimmunology · 2016Review
- Trial watch: Naked and vectored DNA-based anticancer vaccines.Oncoimmunology · 2015Article
- Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy.Oncoimmunology · 2015Review
- Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Trial watch: Tumor-targeting monoclonal antibodies for oncological indications.Oncoimmunology · 2015Review
- Classification of current anticancer immunotherapies.Oncotarget · 2014Review
- Novel immune checkpoint blocker approved for the treatment of advanced melanoma.Oncoimmunology · 2014Article
- Trial Watch: Proteasomal inhibitors for anticancer therapy.Molecular & cellular oncologyReview
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.